

September 22, 2011

PROSTATE CANCER CURE UNITED STATES PATENT APPLICATION - PRORVLYSIN[®]

TAMPA, FL--(September 22, 2011) - **CZ BioMed Corp** announced today they have successfully applied for a United States patent for its new treatment for prostate cancer, PRORVLYSIN[®], a novel oncolytic virotherapy which is a new class of potent, genetically engineered virus, that selectively kills prostate cancer cells. Moreover, negative sexual side effects such as erectile dysfunction or loss of libido appear to be nonexistent. This medical breakthrough will allow CZ BioMed to potentially help millions of people worldwide in their battle against prostate cancer.

As a result of this milestone, CZ BioMed Corp. is continuing discussions with all interested global Bio-Pharma leaders, for partnership arrangements and licensing of the technologies. Simultaneously, the company will begin IND (Investigational-New-Drug) filings with the United States FDA to initiate Phase 1 clinical trials. In the interest of bringing these game-changing treatments to America directly as quickly as possible, international studies are beginning. At this time, CZ BioMed is seeking the participation of patients for clinical trials to be conducted by our staff in our overseas facilities. We have partnerships with only the best, state-of-the-art hospitals and laboratories with the trials being personally conducted and overseen by our medical director, doctors, scientists, and specialists.

PRORVLYSIN[®] is the invention of CZ BioMed Corp. PRORVLYSIN[®] is a genetically modified oncolytic virus that selectively targets and destroys prostate cancer cells, whilst leaving surrounding non-malignant cells unharmed/uninfected. The destruction of these cancer cells occurs either through direct lytic rupture via multiple cycles of viral replication or the subsequent induction of apoptosis, also known as programmed cell death. Thus, PRORVLYSIN[®] is vastly safer to use and easier for the body to process, as compared to traditional chemo – or radio- therapies of tumors, allowing patients to enjoy a much higher quality of life during treatment. A highlight of this point is the fact that the treatment itself is much less menacing and painful, and more drastic procedures, such as removal of the prostate or castration, are not necessary. This would allow for normal sexual function to continue without the negative side effects that go along with the removal of such organs. As a result, it would follow that more men would be inclined to pre-screenings, knowing that early detection could now be treatable without detriment, and by default, save more lives.

PRORVLYSIN[®] specifically kills prostate cancer cells (LNCaP cells), but not normal PCS-440-010 (Human Primary Prostate Epithelial Cells). PRORVLYSIN[®] selectively induced cytopathic effect (CPE) in the LNCaP prostate cancer cells, and had a higher viral titer in these tumor cells than in the normal PCS-440-010 cells 24h post-infection..

PRORVLYSIN[®] was also found to kill PC3 cells when checked 48 hours post-infection. This indicates that PRORVLYSIN[®] has the potential to treat a broad spectrum of prostate cancers.

Moreover, PRORVLYSIN[®] may prove to induce less neutralizing antibodies upon in vivo administration, because of its lower antigenesis as compared to other oncolytic viruses; similar

to our test results with breast cancer cells treated with our BRVLYSIN[®]. This would suggest that PRORVLYSIN[®] can be administered multiple times to allow for maximum effect in eradicating the tumor, without concern for the host body rejecting it or fighting off the treatment.

PRORVLYSIN[®] specifically localizes to the tumor upon direct injection, and does not spread to other healthy tissues or organs due to its genetic modifications. Thus, this procedure is not harming areas of the body that are not currently in danger of the cancer. Intravenous administration for distant cancers is also possible with its use as a pre-cancer vaccination highly plausible at this point due to the virus' ability to exist, and not infect non-cancerous cells.

Prostate cancer is the most common malignancy and the second leading cause of cancer mortality amongst men in the Western world. In the USA, there is an estimated incidence of 217,730 cases and 32,050 deaths in 2010. Up to 40% of men diagnosed with prostate cancer will eventually develop metastatic disease, and although most respond to initial medical or surgical castration, progression to castration resistance is universal. The average survival for patients with castration-resistant prostate cancer is 2-3 years. It continues to be a major cause of cancer related morbidity and mortality, and there is an urgent need for new treatments.

"We are extremely proud of this achievement announced today. This documents our continued, constant efforts to not only discover through research, but develop and refine our virotherapies into treatments that will combat a wide range of cancers for a multitude of people. PRORVLYSIN[®] is but one of many treatments to be brought to market by our dedicated team." ~ Calvin Cao, Founder / Chairman / CEO of CZ BioMed Corp.

About CZ BioMed Corp:

CZ BioMed Corp. is a privately held Biotechnology company based in Tampa, FL, focused on the discovery, development and commercialization of a new class of high-tech biological products for the treatment of a wide variety of human cancers. CZ BioMed products use novel oncolytic viruses that have been genetically engineered to selectively target tumor cells, but not normal healthy cells. The mission of **CZ BioMed Corp.** is rooted in the knowledge of our invention with the products we provide positively affecting the quality of patients lives. Since everything we do, no matter how small, impacts the end product and ultimately people's lives, we accept only the highest ethical and quality standards, both from ourselves and others.

For further information about CZ BioMed Corp. please visit: www.czbiomed.com

Forward Looking Statements

This report includes "*forward-looking statements*" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. The information in this news release includes certain forward-looking statements that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, product development acceptance, and the impact of competitive

services and general economic risks and uncertainties.

September 8, 2011

PROGRESS IN PANCREATIC CANCER CURE RESEARCH PANRVLYSIN[®]

TAMPA, FL--(September 8, 2011) - **CZ BioMed Corp** announced today they have successfully developed a new class of treatment in the fight against pancreatic cancer using oncolytic virotherapy. PANRVLYSIN[®] is a discovery of CZ BioMed Corp. PANRVLYSIN[®] is a novel, genetically engineered common cold-like virus that selectively kills only the pancreatic cancer cells, while leaving the normal and good cells within the body unharmed. Therefore, PANRVLYSIN[®] is vastly safer to use, when compared to traditional chemo - or radio-therapies of tumors, while also providing a much higher quality of life during the treatment period. This medical breakthrough will allow CZ BioMed to potentially help millions of people worldwide in their battle against pancreatic cancer.

PANRVLYSIN[®] was found to effectively kill a variety of pancreatic cancer cell in vitro (within test glass). Additionally, results have shown that PANRVLYSIN[®] induces tumor growth regression in vivo (within a living organism) as well. This new product has been well tolerated in all experimental mice to date, with PANRVLYSIN[®] specifically localizing to the tumor upon its local administration, and has not spread to other tissues or organs. Thus, our unique treatment is highly targeted and not harming areas of the body that are not currently infiltrated by the cancer.

During this process, the primary replication of oncolytic viruses within the cancer cells directly kills the targeted tumor cells. The resultant explosion of each cancer cell activates a cascade of anti-tumor immune responses, including a significant interferon release. These payloads act in concert with the primary oncolysis mechanism to eradicate the pancreatic cancer.

An estimated 43,140 patients have so far been diagnosed with pancreatic cancer in the United States in 2010, and about 36,800 have died from this disease. Pancreatic cancer is the fourth most common cause of cancer deaths, both in the United States and internationally. Pancreatic cancer often has a poor prognosis: for all stages combined, the 1- and 5-year relative survival rates are 25% and 6%, respectively; for local disease, the 5-year survival is approximately 20%, while the median survival for locally advanced and for metastatic disease, which collectively represent over 80% of individuals, is about 10 and 6 months, respectively. Therefore, a safe and effective treatment remains a critical need and is a tremendous opportunity for PANRVLYSIN[®].

For further information: [SEER Stat Fact Sheets: Pancreas](#)

"We are very excited to reach this milestone today. Our hard work and dedication to cure pancreatic cancer has moved one step closer. This breakthrough will allow patients to recover faster, will not destroy the healthy cells and is the definitive next step towards the cure of this deadly disease. As we know, cancer does not discriminate. From notable figures such as Steve Jobs, to our relatives in the next room, we look to the future, for PANRVLYSIN[®] to save

millions of lives and join the elite class of cancer drugs developed by: Roche (RHHBY.pk); Eli Lilly (NYSE: LLY); Amgen Inc. (NASD: AMGN); Dendreon Corp. (NASD: DNDN); Genzyme Corp. (NASD: GENZ); AstraZeneca (NYSE: AZN) and many other respected companies in this relentless pursuit to eradicate cancer." ~ Calvin Cao, Founder/Chairman/CEO of CZ BioMed Corp.

CZ BIOMED CORP - RESEARCH FOR PANCREATIC CANCER CURE - PANRVLYSIN®

As a result of this milestone, CZ BioMed Corp. will now open aggressive discussions with all interested global bio-pharmaceutical leaders, for partnership arrangements and licensing of the technologies. Simultaneously, the company will begin IND (Investigational-New-Drug) filings with the United States FDA to initiate Phase 1 clinical trials. If your company is interested in licensing these technologies, please contact CZ BioMed Corp. at info@czbiomed.com for further details.

About CZ BioMed Corp:

CZ BioMed Corp. is a privately held Biotechnology company based in Tampa, FL, focused on the discovery, development and commercialization of a new class of high-tech biological products for the treatment of a wide variety of human cancers. CZ BioMed products use novel oncolytic viruses that have been genetically engineered to selectively target tumor cells, but not normal healthy cells. The mission of **CZ BioMed Corp.** is rooted in the knowledge of our invention with the products we provide positively affecting the quality of patients lives. Since everything we do, no matter how small, impacts the end product and ultimately people's lives, we accept only the highest ethical and quality standards, both from ourselves and others.

For further information about CZ BioMed Corp. please visit: www.czbiomed.com

Forward Looking Statements

This report includes "*forward-looking statements*" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. The information in this news release includes certain forward-looking statements that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, product development acceptance, and the impact of competitive services and general economic risks and uncertainties.

Aug 23, 2011

CZ BioMed Corp. Names Internationally Renowned Dr. Ronald E. Wheeler, M.D. as Medical Director of its Scientific and Medical Advisory Boards

TAMPA, FL--(August 23, 2011) - **CZ BioMed Corp** , a leading company in the field of

oncolytic virotherapy, providing research, development, commercialization and treatments, pursuant to the eradication of various cancers, announced today the appointment of Dr. Ronald E. Wheeler, M.D., to lead its Medical Advisory Board, in charge of prostate cancer clinical trials studies, worldwide.

CZ BioMed Corp CEO, Calvin Cao, said, We welcome Dr. Wheeler to our advisory boards with enthusiasm. He is a very distinguished and highly recognized international expert with years of cutting edge laboratory and clinical management experience in the fields of urology and prostate cancer. He will be pivotal in the development of both safety and administration protocols for our patent pending oncolytic virotherapy cancer treatments, worldwide. His impeccable track record further adds credibility to our talented staff and supports our goal of eradicating cancers worldwide.

Dr. Wheeler said, With its technologies, patent base, global affiliations, and many successful demonstrated results eradicating tumors in-vitro and in-vivo, CZ BioMed is well positioned to become the breakthrough leader in the fight against cancer. I am excited to be a part of such an innovative company with such excellent humanitarian motivations. I expect us to demonstrate tremendous advances in the treatment of many cancers in the very near future.

About Dr Ronald Wheeler MD: A practicing Urologist for more than 20 years, Dr. Wheeler has focused on male related health issues including impotency and Prostate Diseases associated with BPH, Prostatitis, and Prostate Cancer. He has been a member of the American Urologic Association since 1985 and is a member of the National Institute of Health(NIH) Prostatitis Collaborative.

He is currently Medical Director of the Diagnostic Center for Disease located in Sarasota, FL and of the Prostate Cancer Prevention Foundation.

Other professional highlights include:

- Owner of two patents on Prostatitis Detection and Resolution
- Principal investigator in a Neo-Adjuvant study for Organ Confined Prostate Cancer, by Schering Pharmaceuticals
- A member of the esteemed Royal College of Alternative Medicine (RCAM).
- Certified in High Intensity Focused Ultrasound (HIFU), a novel prostate cancer treatment currently involved in Phase 3 trials at the FDA. Currently treating patients in Canada, Dominican Republic, Mexico, and the Bahamas.
- Author of numerous prostate related articles.
- Member of Advisory boards for several health related corporations and foundations including: Sanofi-Aventis Ocoology, Urology Times, PAACT, Prostate Awareness Foundation, Glaxo Smith Kline, Abbott, and Radiation Centers of America.
- Frequent Speaker on various radio stations and, meetings, and related symposiums.

About CZ BioMed Corp:

CZ BioMed Corp. is a privately held Biotechnology company based in Tampa, FL, focused on the discovery, development and commercialization of a new class of high-tech biological products for the treatment of a wide variety of human cancers. CZ BioMed products use novel oncolytic viruses that have been genetically engineered to selectively target tumor cells, but not normal healthy cells. The mission of **CZ BioMed Corp.** is rooted in the knowledge of our invention with the products we provide positively affecting the quality of patients lives. Since everything we do, no matter how small, impacts the end product and ultimately people's lives, we accept only the highest ethical and quality standards, both from ourselves and others.

For further information about CZ BioMed Corp. please visit: www.czbiomed.com

Forward Looking Statements

This report includes "*forward-looking statements*" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. The information in this news release includes certain forward-looking statements that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, product development acceptance, and the impact of competitive services and general economic risks and uncertainties.

May 3, 2011

**BREAST CANCER CURE
INTERNATIONAL PATENT APPLICATION #
PCT/US2011/000602
CZ BioMed Corp.**

TAMPA, FL--(May 3, 2011) - **CZ BioMed Corp.** announced today they have successfully applied for an international patent for its new treatment for breast cancer, BRVLYSIN, a novel oncolytic virotherapy which is a new class of potent, genetically engineered, common-cold-like virus, that selectively kills breast cancer cells, but not normal healthy cells. This medical breakthrough will allow CZ BioMed to potentially help millions of people worldwide in their battle against cancer. Additional patents are being drafted as of this writing, with global technology protection anticipated.

As a result of this milestone, CZ BioMed Corp. will now open aggressive discussions with all interested global bio-pharma leaders, for partnership arrangements and licensing of the technologies. Simultaneously, the company will begin IND (Investigational-New-Drug) filings with the United States FDA to initiate Phase 1 clinical trials. If your company is interested in licensing these technologies, please contact info@czbiomed.com for further details.

BRVLYSIN is the invention of CZ BioMed Corp. BRVLYSIN is a genetically modified oncolytic virus that selectively targets and destroys breast cancer cells, whilst leaving

surrounding non-malignant cells unharmed. The destruction of these cancer cells occurs either through direct lytic rupture via multiple cycles of viral replication or the subsequent induction of apoptosis, also known as programmed cell death. Thus, BRVLYSIN is vastly safer to use and easier for the body to process, as compared to traditional chemo - or radio-therapies of tumors, allowing patients to enjoy a much higher quality of life during treatment.

BRVLYSIN preferentially kills breast cancer cells both in vitro and in vivo. MDA-MB-231 breast cancer cells and normal CCD-1059SK (Human normal breast fibroblast) were cultured as indicated by ATCC (American Type Culture Collection) instructions, and then infected with the wild type and BRVLYSIN (MOI=5) versions of the virus respectively. BRVLYSIN selectively induced cytopathic effect (CPE) in the MDA-MB-231 breast cancer cells, and had a higher viral titer in these tumor cells than in the normal CCD-1059SK cells 24h post-infection.

BRVLYSIN was also found to kill T-47D cells, a p53- cell like the subject MDA-MB-231's, as well as p53+ breast cancer cells such as MCF7. This indicates that BRVLYSIN has the potential to treat a very broad spectrum of breast cancers.

Moreover, BRVLYSIN induced less neutralizing antibodies upon in vivo administration because of its lower antigenesis as compared to other oncolytic viruses. This suggests that BRVLYSIN can be administered multiple times to allow for maximum effect in eradicating the tumor, without concern for the host body rejecting it or fighting off the treatment.

In an established human breast cancer nude BALB/c mouse model, BRVLYSIN was locally injected into the tumors three times and the sizes of the tumors were significantly reduced by day 8 versus controls. At day 18 post- BRVLYSIN -injection, the sizes of the tumors almost disappeared and have not shown signs of restoration since.

BRVLYSIN specifically localizes to the tumor upon direct injection, and does not spread to other tissues or organs. Thus, this procedure is not harming areas of the body that are not currently in danger of the cancer. Intravenous administration for distant cancers is also possible with its use as a pre-cancer vaccination highly plausible at this point due to the virus' ability to exist, and not infect non-cancerous cells.

Breast cancer is the most common cancer among women, with more than one million new cases identified worldwide each year. An estimated 192,370 patients were newly diagnosed with breast cancer in the United States alone in 2009, and about 40,170 died of the disease. Approximately 24% to 30% of women who have no lymph-node involvement at the time of diagnosis will relapse; the relapse rate for node-positive women is between 50%-60%. The 5-year survival rates for those diagnosed with regional and metastatic disease are 80% and 26%, respectively. Therefore, a safe and effective treatment remains a critical need.

"We are very excited to reach this milestone today. These patents usher in a new era of internationally viable therapies and cooperation between nations to finally eliminate cancer and their current, destructive treatments. BRVLYSIN is the first of many treatments to be brought to light"

~ Calvin Cao, Chairman / CEO / President of CZ BioMed Corp.

About CZ BioMed Corp:

CZ BioMed Corp. is a privately held Biotechnology company based in Tampa, FL, focused

on the discovery, development and commercialization of a new class of high-tech biological products for the treatment of a wide variety of human cancers. CZ BioMed products use novel oncolytic viruses that have been genetically engineered to selectively target tumor cells, but not normal healthy cells. The mission of **CZ BioMed Corp.** is rooted in the knowledge of our invention with the products we provide positively affecting the quality of patients lives. Since everything we do, no matter how small, impacts the end product and ultimately people's lives, we accept only the highest ethical and quality standards, both from ourselves and others.

For further information about CZ BioMed Corp. please visit: www.czbiomed.com

Forward Looking Statements

This report includes "*forward-looking statements*" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. The information in this news release includes certain forward-looking statements that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, product development acceptance, and the impact of competitive services and general economic risks and uncertainties.

Oct 12, 2010 12:23 ET

Research for Cancer Cure -- RVLYSIN® CZ BioMed Corp.

CARSON CITY, NV and TAMPA, FL--(Marketwire - October 12, 2010) - **CZ BioMed Corp.** announced today they have successfully developed a new class of treatment in the fight against cancer using oncolytic virotherapy.

RVLYSIN® is the invention of **CZ BioMed Corp.** RVLYSIN® is a novel, genetically engineered oncolytic virus that selectively kills tumor cells, but does not kill off the normal or good cells within the body. RVLYSIN® is vastly safer to use as compared to traditional chemo -- or radio-therapy of tumors, with a much higher quality of life during treatment.

This new product is well-tolerated in all experimental mice to date. RVLYSIN® specifically localizes to the tumor upon administration, and does not spread to other tissues or organs. Thus, this procedure is not harming areas of the body that are not currently in danger of the cancer.

During this process, the primary replication of oncolytic viruses within the cancer cells will directly kill the targeted tumor cells. The resultant explosion of the cancer cell activates a cascade of anti-tumor immune responses including interferon release. These payloads act in concert with the primary oncolysis mechanism to eradicate the cancer.

There are currently more than 100 different types of cancer. Even though there have been many advancements for the cure, there are still terrifying projected numbers. *An astounding 1,529,560 new cancer cases are projected with an estimated 569,490 people dying

from cancer in the United States in 2010 alone. As a specific example, an estimated 192,370 patients were newly diagnosed with breast cancer in the United States in 2009, and about 40,170 died of the disease. Although advancements in the treatment of breast cancer have led to an improvement in outcomes, the 5-year survival rates for those diagnosed with regional and metastatic diseases are 80% and 26% respectively. Approximately 24% to 30% of women who have no lymph-node involvement at the time of diagnosis will relapse; and the relapse rate for node-positive women is 50% - 60%. Therefore, a safe and effective treatment remains a critical need.

*(<http://www.cancer.gov/cancertopics/what-is-cancer>)

One of our products, **BRVLYSIN** was found to effectively kill different types of breast cancer cells. Also, **BRVLYSIN** induces tumor growth regression in vivo, indicating that **BRVLYSIN** functions as a novel bio-drug fighting against breast cancer.

"We are very excited to reach this milestone today. Our hard work and dedication to cure cancer is another step closer. This breakthrough will allow patients to recover faster, will not destroy the healthy cells and is the next step to the cure of this deadly disease. We hope that in the future our finding will join the elite class of cancer drugs developed by Roche; Eli Lilly; Amgen Inc.; Dendreon Corp.; Genzyme Corp. and many other companies in this relentless pursuit to fight against cancer."

~ Calvin Cao, Chairman/CEO/President of CZ BioMed Corp.

CZ BIOMEDCORP - RESEARCH FOR CANCER CURE- RVLYSIN®

This project is ready to go to *Phase 1* of clinical trial studies. We currently have four (4) patents pending on these key technologies. With that in place, the company is entering a critical period and we are presently looking for key partners to take this project to the next level. We believe we could transform the traditional biological drug development process utilizing a lean approach to generating clinical proof- of -concept (POC) data via a 100% outsourcing model.

Calvin Cao:

Mr. Cao is the founder of CZ BioMed Corp. As an inventor, innovator and bio-entrepreneur, his strategy and commitment is to make CZ Biomed the dominant global company for the discovery and development of a new class of high-tech biological products for the treatment of a wide variety of human cancers.

In 2008, as a chairman and co-founder of Stem Cell Therapy International Corp. he engineered the recent merger of Stem Cell Therapy International and Histostem of S. Korea. Histostem is one of the largest fully accredited cord blood banks in the world, with more than 80,000 cord blood units for use in research and treatments. The successful merger has formed one of the first fully merged Pacific Rim stem cell companies and cord blood repositories with a U.S. entity Amstem Corp.

About CZ BioMed Corp:

CZ BioMed Corp. is a privately held Biotechnology company based in Tampa, FL, focused on the discovery, development and commercialization of a new class of high-tech biological products for the treatment of a wide variety of human cancers. CZ BioMed products use novel oncolytic viruses that have been genetically engineered to selectively target tumor cells, but not normal healthy cells. The mission of **CZ BioMed Corp.** is rooted in the knowledge of our

invention with the products we provide positively affecting the quality of patients lives. Since everything we do, no matter how small, impacts the end product and ultimately people's lives, we accept only the highest ethical and quality standards, both from ourselves and others.

For further information about CZ BioMed Corp. please visit: www.czbiomed.com

Forward Looking Statements

This report includes "*forward-looking statements*" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. The information in this news release includes certain forward-looking statements that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, product development acceptance, and the impact of competitive services and general economic risks and uncertainties.